Dr. Kris on the EML4-ALK Translocation in Lung Cancer

Mark G. Kris, MD
Published: Friday, Mar 25, 2011

Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.

On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).

Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.

On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x